NCT00464282
Completed
Not Applicable
Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer
ConditionsCarcinoma, Non-Small-Cell Lung
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Sponsor
- Gunma University
- Status
- Completed
- Last Updated
- 19 years ago
Overview
Brief Summary
Objective: L-[3-18F]-α-methyltyrosine (FMT) is an amino-acid tracer for PET. We evaluated the diagnostic usefulness of 18F-FMT PET in non-small cell lung cancer (NSCLC) patients. Tumor uptake of 18F-FMT PET was compared with 18F-FDG PET and the correlation with L-type amino acid transporter 1 (LAT1) expression also investigated.
Method: Fifty patients with NSCLC were enrolled in this study, and a pair of PET study with 18F-FMT and 18F-FDG was performed. LAT1 expression and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •proven or suspected non-small cell lung cancer
Exclusion Criteria
- •uncontrolled diabetes mellitus
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Diagnostic Usefulness of Fluorine-18-α-Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis PatientSarcoidosisNCT00369980Gunma University
Completed
Not Applicable
Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung CancerNon-Small Cell Lung CancerNCT00826033Gunma University
Completed
Not Applicable
Evaluation of Thoracic Tumors With 18F-FMT and 18F-FDG PET-CT A Clinicopathological StudyNon-Small Cell Lung CancerNCT00698373Gunma University
Completed
Not Applicable
18F-FET PET/CT in the Management of GliomaGliomaNCT06563024Buddhist Tzu Chi General Hospital36
Recruiting
Phase 2
FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade GliomaGlioma, MalignantNCT06172595Singapore General Hospital22